IP Library Granted Patent US 9,901,639
Granted Patent B2
US 9,901,639 · App. 15/044,859 · Granted Feb 27, 2018

Bone marrow origin progenitor cell or endothelial progenitor cell in combination with DNMT1 gene therapy for vascular repair in metabolic disease

Inventor: Hong Wang (Huntingdon Valley, PA)
Assignee: Temple University—of the Commonwealth System of Higher Education
A61K45/06A61K35/28A61K48/00C12N5/0692
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,901,639
App. No.
15/044,859
Granted
Feb 27, 2018
Kind
B2
Abstract

The present invention provides an isolated population of bone marrow-derived endothelial progenitor cells (EPCs) and uses thereof for the treatment of vascular diseases.

Claims (13)

1. A method of treating a vascular disease in a subject, the method comprising:

administering to a subject in need thereof, wherein the subject has a metabolic disorder an effective amount of CD34 + /Vascular Endothelial Growth Factor Receptor-2 + (VEGFR2 + ) bone marrow-derived endothelial progenitor cells (EPCs) to the subject with a metabolic disorder in need thereof,

wherein the bone marrow-derived EPCs are genetically modified by gene transfer, and

wherein the gene is DNA Methyltransferase-1 (DNMT1).

2. The method of claim 1 , wherein the vascular disease is associated with endothelial injury.

3. The method of claim 1 , wherein the vascular disease is hyperhomocysteinemia (HHcy), hyperlipidemia and diabetes associated vascular injury.

4. The method of claim 1 , wherein the bone marrow-derived EPCs are enriched for CD34 + /VEGFR2 + .

5. The method of claim 1 , wherein the bone marrow-derived EPCs are modified prior to administration to the subject.

6. The method of claim 1 , wherein the bone marrow-derived EPCs are modified during or after administration to the subject.

7. The method of claim 1 , wherein the bone marrow-derived EPCs are administered to the subject by at least one of direct injection, venous infusion, and arterial infusion.

8. The method of claim 1 , wherein the bone marrow-derived EPCs differentiate into endothelial cells in the subject.

9. The method of claim 1 , wherein the subject is also treated, either serially or in parallel, with a combination therapy.

10. The method of claim 9 , wherein the combination therapy comprises administering to the subject at least one active agent selected from the group consisting of a therapeutic agent, an anti-angiogenic or anti-vascular agent, an anti-inflammation agent, a VEGF inhibitor, an antibiotic, an anti-viral agent, an anti-fungal agent, an anti-protozoal agents, a hormone, a radioactive agent, a toxin, an anesthetic, and any combinations thereof.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 19, 2024
From: TEMPLE UNIV OF THE COMMONWEALTH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 066356/0037 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2016
From: WANG, HONG
To: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 037745/0030 →
Continuity (2)
Provisional Application 62115979 · Feb 13, 2015
Related Publication 20160235789A1 · Aug 18, 2016